ArticleCancers2026

Clinical Outcomes of Second-Line Amrubicin and Platinum-Based Doublet Chemotherapy in Patients with Extrapulmonary Neuroendocrine Carcinoma: A Multicenter Retrospective Study.

Nana Yamakita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.